← Leaderboards
Paul David Olivo
Apath, Llc
$7,995,327
Attributed
$7,995,327
Total exposure
16
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.9M · FY2005–18$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$7,995,327 · 16
By mechanism
R44$3,684,488 · 5
R43$1,823,051 · 8
R01$1,350,000 · 1
R41$741,038 · 1
R21$396,750 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Technology /Technique Development”
- Eric S Lander · Whitehead Institute For Biomedical Res$242,268,294
- Richard K. Wilson · Washington University$145,541,485
- Robert H Waterston · Washington University$144,225,057
- Ronald Wayne Davis · Stanford University$43,786,494
- Andrzej Joachimiak Joachimiak · University Of Chicago$33,231,516
- Deirdre R. Meldrum · University Of Washington$26,048,264
Research focus
Technology /Technique DevelopmentAntiviral AgentsDrug Screening /EvaluationRepliconBioterrorism /Chemical WarfareCell LineBioassayBiotechnologyDrug Discovery /IsolationTissue /Cell CultureChemical Registry /ResourceGene ExpressionHepatitis C VirusPolymerase Chain ReactionReporter GenesVirus GeneticsHigh Throughput TechnologyRespiratory Syncytial VirusRna VirusTranscription FactorDiagnosis Design /EvaluationPlasmidsTransfectionCommunicable Disease Diagnosis
Grant awards (25)
A Novel Inhibitor of the Classical Pathway of Complement$254,235
R43 · FY2018 · HL · contact PI
Transgenic indicator cells for influenza virus$272,949
R44 · FY2006 · AI · contact PI
Therapeutics for Ebola virus$1,350,000
R01 · FY2005 · AI
Replicon-based screening for inhibitors of alphaviruses$475,049
R43 · FY2005 · AI
Molecular tools for Bunyavirus antiviral screening$413,699
R41 · FY2005 · AI
Indicator cells for antiviral screening for filoviruses$368,309
R44 · FY2005 · AI
Transgenic indicator cells for influenza virus$308,949
R44 · FY2005 · AI
Replicon-based screening for inhibitors of alphaviruses$483,532
R43 · FY2004 · AI
Screening for anti-RSV compounds with indicator cells$359,466
R44 · FY2004 · AI
Indicator cells for antiviral screening for filoviruses$357,582
R44 · FY2004 · AI
Molecular tools for Bunyavirus antiviral screening$327,339
R41 · FY2004 · AI
Transgenic indicator cells for influenza virus$106,026
R44 · FY2004 · AI
Screening for anti-RSV compounds with indicator cells$411,213
R44 · FY2003 · AI
Antiviral Screening Assays Based on HCV Replicons$320,675
R44 · FY2003 · AI
Screening for antivirals against flaviviruses$209,250
R21 · FY2003 · AI
Multiplexed Gene Assays by Microtiter Plate Microarrays$111,600
R43 · FY2003 · AI
Construction of a Respiratory Syncytial Virus Replicon$100,000
R43 · FY2003 · AI
Antiviral Screening Assays Based on HCV Replicons$429,325
R44 · FY2002 · AI
Hepatitis C Virus RNA Quantitation Using The 3'NTR$371,356
R44 · FY2002 · AI
Screening for antivirals against flaviviruses$187,500
R21 · FY2002 · AI
Indicator cells for antiviral screening for filoviruses$100,000
R43 · FY2002 · AI
Antiviral screening against multiple viruses$100,000
R43 · FY2002 · AI
Hepatitis C Virus RNA Quantitation Using The 3'NTR$378,638
R44 · FY2001 · AI
Antiviral Screening Assays Based on HCV Replicons$99,395
R43 · FY2001 · AI
CELLS FOR DETECTING NEGATIVE-STRAND RNA VIRUSES$99,240
R43 · FY2000 · AI